{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:55:37Z","timestamp":1790844937934,"version":"4.1.0"},"reference-count":177,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer is a systemic disease in which the tumor interacts with the entirety of the body to promote tumor pathogenesis and progression. While tremendous efforts have focused on understanding the local immune responses in the primary site because of the noticeable immunosuppressive characteristics in the tumor microenvironment (TME), the interaction between the tumor and the host\u2019s systemic response has not received much attention. These interactions influence primary tumor growth and treatment responses and can further facilitate tumor dissemination and condition distant tissues for metastatic colonization. In this review, we summarize the reciprocal interactions between the primary tumor and the systemic environment throughout cancer development, including pre-metastatic niche formation and metastatic progression, with particular emphasis on tumor-draining lymph nodes (TDLNs), bone marrow (BM), and blood circulation. By integrating these perspectives, this review aims to provide a more comprehensive understanding of tumor development within the whole-body context, thereby highlighting the development and optimization of  strategies in cancer diagnosis, prognosis, and treatment that account for the systemic nature of the disease.<\/jats:p>","DOI":"10.1007\/s10555-026-10383-6","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:10:17Z","timestamp":1790838617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanisms of systemic immune modulation in tumor development: Interactions across lymph nodes, bone marrow, and blood"],"prefix":"10.1007","volume":"45","author":[{"given":"Xiaofei","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh","family":"Ph\u1ea1m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja D.","family":"de Gruijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke F.","family":"Fransen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2544-544X","authenticated-orcid":false,"given":"Febe","family":"van Maldegem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"3","key":"10383_CR1","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K. E., & Joyce, J. A. (2023). The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell, 41(3), 374\u2013403.","journal-title":"Cancer Cell"},{"issue":"26","key":"10383_CR2","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1200\/JCO.2010.28.4257","volume":"28","author":"SS McAllister","year":"2010","unstructured":"McAllister, S. S., & Weinberg, R. A. (2010). Tumor-host interactions: A far-reaching relationship. Journal of Clinical Oncology, 28(26), 4022\u20138.","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10383_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia, F., Sanseviero, E., & Gabrilovich, D. I. (2021). Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nature Reviews Immunology, 21(8), 485\u2013498.","journal-title":"Nature Reviews Immunology"},{"issue":"1","key":"10383_CR4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/imr.12399","volume":"271","author":"G Gasteiger","year":"2016","unstructured":"Gasteiger, G., Ataide, M., & Kastenm\u00fcller, W. (2016). Lymph node - an organ for T-cell activation and pathogen defense. Immunological Reviews, 271(1), 200\u2013220.","journal-title":"Immunological Reviews"},{"issue":"12","key":"10383_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/s41568-024-00752-0","volume":"24","author":"N Rabas","year":"2024","unstructured":"Rabas, N., et al. (2024). Cancer-induced systemic pre-conditioning of distant organs: Building a niche for metastatic cells. Nature Reviews Cancer, 24(12), 829\u2013849.","journal-title":"Nature Reviews Cancer"},{"issue":"7069","key":"10383_CR6","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/nature04186","volume":"438","author":"RN Kaplan","year":"2005","unstructured":"Kaplan, R. N., et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438(7069), 820\u2013827.","journal-title":"Nature"},{"issue":"5","key":"10383_CR7","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrc.2017.6","volume":"17","author":"H Peinado","year":"2017","unstructured":"Peinado, H., et al. (2017). Pre-metastatic niches: Organ-specific homes for metastases. Nature Reviews Cancer, 17(5), 302\u2013317.","journal-title":"Nature Reviews Cancer"},{"issue":"3","key":"10383_CR8","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.ccell.2023.02.018","volume":"41","author":"L Patras","year":"2023","unstructured":"Patras, L., et al. (2023). Immune determinants of the pre-metastatic niche. Cancer Cell, 41(3), 546\u2013572.","journal-title":"Cancer Cell"},{"issue":"1","key":"10383_CR9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41392-024-01937-7","volume":"9","author":"Y Wang","year":"2024","unstructured":"Wang, Y., et al. (2024). Pre-metastatic niche: Formation, characteristics and therapeutic implication. Signal Transduction and Targeted Therapy, 9(1), 236.","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"64","key":"10383_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg7836","volume":"6","author":"KA Connolly","year":"2021","unstructured":"Connolly, K. A., et al. (2021). A reservoir of stem-like CD8(+) T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response. Science Immunology, 6(64), Article eabg7836.","journal-title":"Science Immunology"},{"issue":"5","key":"10383_CR11","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","volume":"20","author":"M Labelle","year":"2011","unstructured":"Labelle, M., Begum, S., & Hynes, R. O. (2011). Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell, 20(5), 576\u2013590.","journal-title":"Cancer Cell"},{"issue":"5","key":"10383_CR12","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41577-023-00965-8","volume":"24","author":"P Cruz de Casas","year":"2024","unstructured":"Cruz de Casas, P., et al. (2024). Same yet different - how lymph node heterogeneity affects immune responses. Nature Reviews Immunology, 24(5), 358\u2013374.","journal-title":"Nature Reviews Immunology"},{"key":"10383_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.643291","volume":"12","author":"KM van Pul","year":"2021","unstructured":"van Pul, K. M., et al. (2021). Immunotherapy goes local: The central role of lymph nodes in driving tumor infiltration and efficacy. Frontiers in Immunology, 12, Article 643291.","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10383_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.trecan.2023.09.006","volume":"10","author":"I Delclaux","year":"2024","unstructured":"Delclaux, I., et al. (2024). The tumor-draining lymph node as a reservoir for systemic immune surveillance. Trends in Cancer, 10(1), 28\u201337.","journal-title":"Trends in Cancer"},{"issue":"10","key":"10383_CR15","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1007\/s00262-019-02330-y","volume":"68","author":"J Rotman","year":"2019","unstructured":"Rotman, J., et al. (2019). Unlocking the therapeutic potential of primary tumor-draining lymph nodes. Cancer Immunology, Immunotherapy, 68(10), 1681\u20131688.","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"1","key":"10383_CR16","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1038\/s41467-018-04524-x","volume":"9","author":"R Alonso","year":"2018","unstructured":"Alonso, R., et al. (2018). Induction of anergic or regulatory tumor-specific CD4(+) T cells in the tumor-draining lymph node. Nature Communications, 9(1), 2113.","journal-title":"Nature Communications"},{"issue":"1","key":"10383_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s40425-019-0605-1","volume":"7","author":"KM van Pul","year":"2019","unstructured":"van Pul, K. M., et al. (2019). Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node. Journal for Immunotherapy of Cancer, 7(1), 133.","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"11","key":"10383_CR18","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1158\/2326-6066.CIR-17-0110","volume":"5","author":"M van den Hout","year":"2017","unstructured":"van den Hout, M., et al. (2017). Melanoma sequentially suppresses different DC subsets in the sentinel lymph node, affecting disease spread and recurrence. Cancer Immunology Research, 5(11), 969\u2013977.","journal-title":"Cancer Immunology Research"},{"issue":"63","key":"10383_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg3551","volume":"6","author":"H du Bois","year":"2021","unstructured":"du Bois, H., Heim, T. A., & Lund, A. W. (2021). Tumor-draining lymph nodes: At the crossroads of metastasis and immunity. Science Immunology, 6(63), Article eabg3551.","journal-title":"Science Immunology"},{"issue":"1","key":"10383_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-60243-y","volume":"14","author":"IV Gon\u00e7alves","year":"2024","unstructured":"Gon\u00e7alves, I. V., et al. (2024). Dynamic changes in B cell subpopulations in response to triple-negative breast cancer development. Scientific Reports, 14(1), Article 11576.","journal-title":"Scientific Reports"},{"key":"10383_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.825287","volume":"13","author":"DAP Louie","year":"2022","unstructured":"Louie, D. A. P., et al. (2022). Tumor-draining lymph node reconstruction promotes B cell activation during E0771 mouse breast cancer growth. Frontiers in Pharmacology, 13, Article 825287.","journal-title":"Frontiers in Pharmacology"},{"issue":"4","key":"10383_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer, G., et al. (2022). Immunogenic cell stress and death. Nature Immunology, 23(4), 487\u2013500.","journal-title":"Nature Immunology"},{"issue":"1","key":"10383_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-28830-7","volume":"13","author":"K Bucher","year":"2023","unstructured":"Bucher, K., et al. (2023). Extra-viral DNA in adeno-associated viral vector preparations induces TLR9-dependent innate immune responses in human plasmacytoid dendritic cells. Scientific Reports, 13(1), Article 1890.","journal-title":"Scientific Reports"},{"issue":"9","key":"10383_CR24","doi-asserted-by":"publisher","first-page":"4580","DOI":"10.1128\/JVI.76.9.4580-4590.2002","volume":"76","author":"AK Zaiss","year":"2002","unstructured":"Zaiss, A. K., et al. (2002). Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. Journal of Virology, 76(9), 4580\u20134590.","journal-title":"Journal of Virology"},{"issue":"6282","key":"10383_CR25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1126\/science.aaf1328","volume":"352","author":"F Pucci","year":"2016","unstructured":"Pucci, F., et al. (2016). SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science, 352(6282), 242\u2013246.","journal-title":"Science"},{"issue":"11","key":"10383_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166680","volume":"11","author":"T Shiota","year":"2016","unstructured":"Shiota, T., et al. (2016). The clinical significance of CD169-positive lymph node macrophage in patients with breast cancer. PLoS One, 11(11), Article e0166680.","journal-title":"PLoS One"},{"issue":"2","key":"10383_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1084\/jem.20122183","volume":"210","author":"CW Yang","year":"2013","unstructured":"Yang, C. W., & Unanue, E. R. (2013). Neutrophils control the magnitude and spread of the immune response in a thromboxane A2-mediated process. Journal of Experimental Medicine, 210(2), 375\u201387.","journal-title":"Journal of Experimental Medicine"},{"issue":"7","key":"10383_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111171","volume":"40","author":"E Pylaeva","year":"2022","unstructured":"Pylaeva, E., et al. (2022). During early stages of cancer, neutrophils initiate anti-tumor immune responses in tumor-draining lymph nodes. Cell Reports, 40(7), Article 111171.","journal-title":"Cell Reports"},{"issue":"1","key":"10383_CR29","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1038\/s41467-024-46685-y","volume":"15","author":"L L\u00f3pez","year":"2024","unstructured":"L\u00f3pez, L., et al. (2024). Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors. Nature Communications, 15(1), 2280.","journal-title":"Nature Communications"},{"issue":"5","key":"10383_CR30","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.immuni.2008.08.013","volume":"29","author":"EJ Allenspach","year":"2008","unstructured":"Allenspach, E. J., et al. (2008). Migratory and lymphoid-resident dendritic cells cooperate to efficiently prime naive CD4 T cells. Immunity, 29(5), 795\u2013806.","journal-title":"Immunity"},{"issue":"5","key":"10383_CR31","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"A Del Prete","year":"2023","unstructured":"Del Prete, A., et al. (2023). Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cellular & Molecular Immunology, 20(5), 432\u2013447.","journal-title":"Cellular & Molecular Immunology"},{"issue":"100","key":"10383_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adq8843","volume":"9","author":"A Chudnovskiy","year":"2024","unstructured":"Chudnovskiy, A., et al. (2024). Proximity-dependent labeling identifies dendritic cells that drive the tumor-specific CD4(+) T cell response. Science Immunology, 9(100), Article eadq8843.","journal-title":"Science Immunology"},{"issue":"3","key":"10383_CR33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C., et al. (2019). Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nature Immunology, 20(3), 326\u2013336.","journal-title":"Nature Immunology"},{"issue":"10","key":"10383_CR34","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.immuni.2021.08.026","volume":"54","author":"JM Schenkel","year":"2021","unstructured":"Schenkel, J. M., et al. (2021). Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1(+) CD8(+) T cells in tumor-draining lymph nodes. Immunity, 54(10), 2338-2353.e6.","journal-title":"Immunity"},{"issue":"4","key":"10383_CR35","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.ccell.2023.03.009","volume":"41","author":"JA Pai","year":"2023","unstructured":"Pai, J. A., et al. (2023). Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. Cancer Cell, 41(4), 776-790.e7.","journal-title":"Cancer Cell"},{"issue":"8","key":"10383_CR36","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost, K. E., et al. (2019). Clonal replacement of tumor-specific T cells following PD-1 blockade. Nature Medicine, 25(8), 1251\u20131259.","journal-title":"Nature Medicine"},{"issue":"1","key":"10383_CR37","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s43018-021-00292-8","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu, B., et al. (2022). Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nature Cancer, 3(1), 108\u2013121.","journal-title":"Nature Cancer"},{"key":"10383_CR38","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.183080","author":"E Engelbrecht","year":"2025","unstructured":"Engelbrecht, E., et al. (2025). Single-cell transcriptomics of melanoma sentinel lymph nodes identifies immune cell signatures associated with metastasis. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.183080","journal-title":"JCI Insight"},{"issue":"4","key":"10383_CR39","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/ijc.34555","volume":"153","author":"K Piersiala","year":"2023","unstructured":"Piersiala, K., et al. (2023). Regulatory B cells producing IL-10 are increased in human tumor draining lymph nodes. International Journal of Cancer, 153(4), 854\u2013866.","journal-title":"International Journal of Cancer"},{"issue":"6","key":"10383_CR40","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/j.immuni.2026.04.017","volume":"59","author":"N Nathan","year":"2026","unstructured":"Nathan, N., et al. (2026). Tumor-draining lymph nodes in ovarian cancer lack germinal centers but harbor tumor-reactive memory B cells clonally linked to intra-tumoral B cells. Immunity, 59(6), 1743-1757.e10.","journal-title":"Immunity"},{"issue":"18","key":"10383_CR41","doi-asserted-by":"publisher","first-page":"9459","DOI":"10.7150\/thno.113940","volume":"15","author":"GL Su","year":"2025","unstructured":"Su, G. L., et al. (2025). Dissecting tertiary lymphoid structures in cancer: Maturation, localization and density. Theranostics, 15(18), 9459\u20139485.","journal-title":"Theranostics"},{"key":"10383_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101469","volume":"23","author":"K Piersiala","year":"2022","unstructured":"Piersiala, K., et al. (2022). Tumour-draining lymph nodes in head and neck cancer are characterized by accumulation of CTLA-4 and PD-1 expressing Treg cells. Translational Oncology, 23, Article 101469.","journal-title":"Translational Oncology"},{"issue":"10","key":"10383_CR43","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1158\/1078-0432.CCR-22-0214","volume":"28","author":"AW Lund","year":"2022","unstructured":"Lund, A. W. (2022). Standing watch: Immune activation and failure in melanoma sentinel lymph nodes. Clinical Cancer Research, 28(10), 1996\u20131998.","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10383_CR44","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41467-020-17046-2","volume":"11","author":"NG N\u00fa\u00f1ez","year":"2020","unstructured":"N\u00fa\u00f1ez, N. G., et al. (2020). Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients. Nature Communications, 11(1), 3272.","journal-title":"Nature Communications"},{"issue":"6","key":"10383_CR45","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/pin.13430","volume":"74","author":"S Suzuki","year":"2024","unstructured":"Suzuki, S., et al. (2024). Regulatory T-cells activated in metastatic draining lymph nodes possibly suppress cancer immunity in cancer tissues of head and neck squamous cell cancer. Pathology International, 74(6), 327\u2013336.","journal-title":"Pathology International"},{"key":"10383_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003325","author":"S Jiao","year":"2022","unstructured":"Jiao, S., et al. (2022). Intratumor expanded T cell clones can be non-sentinel lymph node derived in breast cancer revealed by single-cell immune profiling. Journal for Immunotherapy of Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-003325","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"3","key":"10383_CR47","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1158\/0008-5472.CAN-10-1797","volume":"71","author":"JP Hindley","year":"2011","unstructured":"Hindley, J. P., et al. (2011). Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Research, 71(3), 736\u2013746.","journal-title":"Cancer Research"},{"issue":"11","key":"10383_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114938","volume":"43","author":"BL Jamison","year":"2024","unstructured":"Jamison, B. L., et al. (2024). An IL-2 mutein increases regulatory T cell suppression of dendritic cells via IL-10 and CTLA-4 to promote T cell anergy. Cell Reports, 43(11), Article 114938.","journal-title":"Cell Reports"},{"issue":"6","key":"10383_CR49","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cell.2023.02.021","volume":"186","author":"MK Rahim","year":"2023","unstructured":"Rahim, M. K., et al. (2023). Dynamic CD8(+) T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell, 186(6), 1127-1143.e18.","journal-title":"Cell"},{"issue":"1","key":"10383_CR50","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1038\/s41467-020-15886-6","volume":"11","author":"C Zhang","year":"2020","unstructured":"Zhang, C., et al. (2020). Mapping the spreading routes of lymphatic metastases in human colorectal cancer. Nature Communications, 11(1), 1993.","journal-title":"Nature Communications"},{"issue":"7","key":"10383_CR51","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/s41588-020-0633-2","volume":"52","author":"JG Reiter","year":"2020","unstructured":"Reiter, J. G., et al. (2020). Lymph node metastases develop through a wider evolutionary bottleneck than distant metastases. Nature Genetics, 52(7), 692\u2013700.","journal-title":"Nature Genetics"},{"issue":"11","key":"10383_CR52","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.cell.2022.04.019","volume":"185","author":"NE Reticker-Flynn","year":"2022","unstructured":"Reticker-Flynn, N. E., et al. (2022). Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell, 185(11), 1924-1942.e23.","journal-title":"Cell"},{"key":"10383_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003623","author":"AM Heeren","year":"2021","unstructured":"Heeren, A. M., et al. (2021). Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth. Journal for Immunotherapy of Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-003623","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10383_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2021.104296","volume":"362","author":"Q Lahmar","year":"2021","unstructured":"Lahmar, Q., et al. (2021). Monocytic myeloid-derived suppressor cells home to tumor-draining lymph nodes via CCR2 and locally modulate the immune response. Cellular Immunology, 362, Article 104296.","journal-title":"Cellular Immunology"},{"issue":"10","key":"10383_CR55","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1158\/1078-0432.CCR-21-0664","volume":"28","author":"K Yaddanapudi","year":"2022","unstructured":"Yaddanapudi, K., et al. (2022). Single-cell immune mapping of melanoma sentinel lymph nodes reveals an actionable immunotolerant microenvironment. Clinical Cancer Research, 28(10), 2069\u20132081.","journal-title":"Clinical Cancer Research"},{"issue":"8","key":"10383_CR56","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.ccell.2022.06.009","volume":"40","author":"A van Krimpen","year":"2022","unstructured":"van Krimpen, A., et al. (2022). Immune suppression in the tumor-draining lymph node corresponds with distant disease recurrence in patients with melanoma. Cancer Cell, 40(8), 798\u2013799.","journal-title":"Cancer Cell"},{"issue":"9","key":"10383_CR57","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/ni.3492","volume":"17","author":"A Riedel","year":"2016","unstructured":"Riedel, A., et al. (2016). Tumor-induced stromal reprogramming drives lymph node transformation. Nature Immunology, 17(9), 1118\u20131127.","journal-title":"Nature Immunology"},{"key":"10383_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020211","author":"T Bekkhus","year":"2021","unstructured":"Bekkhus, T., et al. (2021). Remodeling of the lymph node high endothelial venules reflects tumor invasiveness in breast cancer and is associated with dysregulation of perivascular stromal cells. Cancers. https:\/\/doi.org\/10.3390\/cancers13020211","journal-title":"Cancers"},{"key":"10383_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1449291","volume":"15","author":"PJ Lei","year":"2024","unstructured":"Lei, P. J., et al. (2024). Lymphatic system regulation of anti-cancer immunity and metastasis. Frontiers in Immunology, 15, Article 1449291.","journal-title":"Frontiers in Immunology"},{"issue":"11","key":"10383_CR60","volume":"10","author":"Q Zhang","year":"2023","unstructured":"Zhang, Q., et al. (2023). ETV4 mediated tumor-associated neutrophil infiltration facilitates lymphangiogenesis and lymphatic metastasis of bladder cancer. Advanced Science (Weinheim an der Bergstrasse, Germany), 10(11), Article e2205613.","journal-title":"Advanced Science (Weinheim an der Bergstrasse, Germany)"},{"issue":"12","key":"10383_CR61","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.15252\/emmm.201606914","volume":"9","author":"SC Huang","year":"2017","unstructured":"Huang, S. C., et al. (2017). TGF-\u03b21 secreted by Tregs in lymph nodes promotes breast cancer malignancy via up-regulation of IL-17RB. EMBO Molecular Medicine, 9(12), 1660\u20131680.","journal-title":"EMBO Molecular Medicine"},{"key":"10383_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.816506","volume":"12","author":"T Li","year":"2022","unstructured":"Li, T., et al. (2022). The lymph node microenvironment may invigorate cancer cells with enhanced metastatic capacities. Frontiers in Oncology, 12, Article 816506.","journal-title":"Frontiers in Oncology"},{"issue":"12","key":"10383_CR63","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1158\/1078-0432.CCR-25-3296","volume":"32","author":"Y Long","year":"2026","unstructured":"Long, Y., et al. (2026). Excessive dissection of nonmetastatic tumor-draining lymph nodes impairs immunotherapy efficacy in recurrent biliary tract cancer. Clinical Cancer Research, 32(12), 2467\u20132478.","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10383_CR64","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/JS9.0000000000000774","volume":"110","author":"H Deng","year":"2024","unstructured":"Deng, H., et al. (2024). Impact of lymphadenectomy extent on immunotherapy efficacy in postresectional recurred non-small cell lung cancer: A multi-institutional retrospective cohort study. International Journal of Surgery, 110(1), 238\u2013252.","journal-title":"International Journal of Surgery"},{"issue":"1","key":"10383_CR65","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1038\/s41467-024-49873-y","volume":"15","author":"I Telarovic","year":"2024","unstructured":"Telarovic, I., et al. (2024). Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease. Nature Communications, 15(1), 5500.","journal-title":"Nature Communications"},{"issue":"18","key":"10383_CR66","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank, C. U., et al. (2024). Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. New England Journal of Medicine, 391(18), 1696\u20131708.","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10383_CR67","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde, P. M., et al. (2022). Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. New England Journal of Medicine, 386(21), 1973\u20131985.","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10383_CR68","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1158\/2326-6066.CIR-14-0165","volume":"3","author":"BJ Sluijter","year":"2015","unstructured":"Sluijter, B. J., et al. (2015). Arming the melanoma sentinel lymph node through local administration of CpG-B and GM-CSF: Recruitment and activation of BDCA3\/CD141(+) dendritic cells and enhanced cross-presentation. Cancer Immunology Research, 3(5), 495\u2013505.","journal-title":"Cancer Immunology Research"},{"issue":"4","key":"10383_CR69","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00262-016-1811-z","volume":"65","author":"MF van den Hout","year":"2016","unstructured":"van den Hout, M. F., et al. (2016). Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node. Cancer Immunology, Immunotherapy, 65(4), 405\u2013415.","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"19","key":"10383_CR70","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.1158\/1078-0432.CCR-17-0944","volume":"23","author":"BD Koster","year":"2017","unstructured":"Koster, B. D., et al. (2017). Local adjuvant treatment with low-dose CpG-B offers durable protection against disease recurrence in clinical stage I-II melanoma: Data from two randomized phase II trials. Clinical Cancer Research, 23(19), 5679\u20135686.","journal-title":"Clinical Cancer Research"},{"issue":"73","key":"10383_CR71","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abn8097","volume":"7","author":"KM van Pul","year":"2022","unstructured":"van Pul, K. M., et al. (2022). Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic T(reg) reduction and effector T cell activation. Science Immunology, 7(73), Article eabn8097.","journal-title":"Science Immunology"},{"issue":"3","key":"10383_CR72","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1182\/blood-2009-02-206870","volume":"114","author":"Y Lee","year":"2009","unstructured":"Lee, Y., et al. (2009). Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: Changing strategies for cancer treatment. Blood, 114(3), 589\u2013595.","journal-title":"Blood"},{"issue":"1","key":"10383_CR73","doi-asserted-by":"publisher","first-page":"7015","DOI":"10.1038\/s41467-022-34676-w","volume":"13","author":"LB Darragh","year":"2022","unstructured":"Darragh, L. B., et al. (2022). Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors. Nature Communications, 13(1), 7015.","journal-title":"Nature Communications"},{"issue":"5","key":"10383_CR74","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.ijrobp.2009.10.014","volume":"76","author":"A Battaglia","year":"2010","unstructured":"Battaglia, A., et al. (2010). Selective changes in the immune profile of tumor-draining lymph nodes after different neoadjuvant chemoradiation regimens for locally advanced cervical cancer. International Journal of Radiation Oncology, Biology, Physics, 76(5), 1546\u20131553.","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10383_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1186479","volume":"13","author":"C Pasquier","year":"2023","unstructured":"Pasquier, C., et al. (2023). Impact of radiation on host immune system in patients treated with chemoradiotherapy and durvalumab consolidation for unresectable locally advanced non-small cell lung cancer. Frontiers in Oncology, 13, Article 1186479.","journal-title":"Frontiers in Oncology"},{"key":"10383_CR76","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124507","author":"MF Fransen","year":"2018","unstructured":"Fransen, M. F., et al. (2018). Tumor-draining lymph nodes are pivotal in PD-1\/PD-L1 checkpoint therapy. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.124507","journal-title":"JCI Insight"},{"issue":"5","key":"10383_CR77","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41580-019-0103-9","volume":"20","author":"S Pinho","year":"2019","unstructured":"Pinho, S., & Frenette, P. S. (2019). Haematopoietic stem cell activity and interactions with the niche. Nature Reviews Molecular Cell Biology, 20(5), 303\u2013320.","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"7","key":"10383_CR78","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrc.2016.52","volume":"16","author":"SB Coffelt","year":"2016","unstructured":"Coffelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016). Neutrophils in cancer: Neutral no more. Nature Reviews Cancer, 16(7), 431\u201346.","journal-title":"Nature Reviews Cancer"},{"issue":"7","key":"10383_CR79","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.immuni.2024.05.007","volume":"57","author":"PF Rodrigues","year":"2024","unstructured":"Rodrigues, P. F., et al. (2024). Progenitors of distinct lineages shape the diversity of mature type 2 conventional dendritic cells. Immunity, 57(7), 1567-1585.e5.","journal-title":"Immunity"},{"issue":"1","key":"10383_CR80","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li, K., et al. (2021). Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduction and Targeted Therapy, 6(1), 362.","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"2","key":"10383_CR81","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","volume":"19","author":"F Veglia","year":"2018","unstructured":"Veglia, F., Perego, M., & Gabrilovich, D. (2018). Myeloid-derived suppressor cells coming of age. Nature Immunology, 19(2), 108\u2013119.","journal-title":"Nature Immunology"},{"issue":"11","key":"10383_CR82","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.1073\/pnas.1320753111","volume":"111","author":"WC Wu","year":"2014","unstructured":"Wu, W. C., et al. (2014). Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 111(11), 4221\u20136.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"10383_CR83","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1002\/eji.201646552","volume":"46","author":"JM Moreau","year":"2016","unstructured":"Moreau, J. M., et al. (2016). Tumor-secreted products repress B-cell lymphopoiesis in a murine model of breast cancer. European Journal of Immunology, 46(12), 2835\u20132841.","journal-title":"European Journal of Immunology"},{"key":"10383_CR84","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221757","author":"S Kim","year":"2023","unstructured":"Kim, S., et al. (2023). IL-6 selectively suppresses cDC1 specification via C\/EBP\u03b2. Journal of Experimental Medicine. https:\/\/doi.org\/10.1084\/jem.20221757","journal-title":"Journal of Experimental Medicine"},{"issue":"8","key":"10383_CR85","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1158\/2326-6066.CIR-21-0946","volume":"11","author":"CA James","year":"2023","unstructured":"James, C. A., et al. (2023). Systemic alterations in type-2 Conventional dendritic cells lead to impaired tumor immunity in pancreatic cancer. Cancer Immunology Research, 11(8), 1055\u20131067.","journal-title":"Cancer Immunology Research"},{"key":"10383_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1458035","volume":"15","author":"AO Yam","year":"2024","unstructured":"Yam, A. O., et al. (2024). Neutrophils under the microscope: Neutrophil dynamics in infection, inflammation, and cancer revealed using intravital imaging. Frontiers in Immunology, 15, Article 1458035.","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10383_CR87","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41392-025-02242-7","volume":"10","author":"Y Zhou","year":"2025","unstructured":"Zhou, Y., et al. (2025). Therapeutic potential of tumor-associated neutrophils: Dual role and phenotypic plasticity. Signal Transduction and Targeted Therapy, 10(1), 178.","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10383_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.557586","volume":"11","author":"N Karin","year":"2020","unstructured":"Karin, N. (2020). The development and homing of myeloid-derived suppressor cells: From a two-stage model to a multistep narrative. Frontiers in Immunology, 11, Article 557586.","journal-title":"Frontiers in Immunology"},{"issue":"7","key":"10383_CR89","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ccell.2025.04.007","volume":"43","author":"H Garner","year":"2025","unstructured":"Garner, H., et al. (2025). Understanding and reversing mammary tumor-driven reprogramming of myelopoiesis to reduce metastatic spread. Cancer Cell, 43(7), 1279-1295.e9.","journal-title":"Cancer Cell"},{"issue":"5","key":"10383_CR90","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.stem.2023.04.005","volume":"30","author":"X Hao","year":"2023","unstructured":"Hao, X., et al. (2023). Osteoprogenitor-GMP crosstalk underpins solid tumor-induced systemic immunosuppression and persists after tumor removal. Cell Stem Cell, 30(5), 648-664.e8.","journal-title":"Cell Stem Cell"},{"issue":"3","key":"10383_CR91","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2005-10-4162","volume":"108","author":"HK Kim","year":"2006","unstructured":"Kim, H. K., et al. (2006). G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood, 108(3), 812\u2013820.","journal-title":"Blood"},{"issue":"8","key":"10383_CR92","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1158\/0008-5472.CAN-05-3842","volume":"66","author":"M Wislez","year":"2006","unstructured":"Wislez, M., et al. (2006). High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Research, 66(8), 4198\u20134207.","journal-title":"Cancer Research"},{"issue":"6","key":"10383_CR93","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","volume":"21","author":"Y Pylayeva-Gupta","year":"2012","unstructured":"Pylayeva-Gupta, Y., et al. (2012). Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell, 21(6), 836\u2013847.","journal-title":"Cancer Cell"},{"issue":"1","key":"10383_CR94","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41413-023-00255-y","volume":"11","author":"EJ Lee","year":"2023","unstructured":"Lee, E. J., et al. (2023). Mobilization of monocytic myeloid-derived suppressor cells is regulated by PTH1R activation in bone marrow stromal cells. Bone Res, 11(1), 22.","journal-title":"Bone Res"},{"issue":"7355","key":"10383_CR95","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature10138","volume":"475","author":"BZ Qian","year":"2011","unstructured":"Qian, B. Z., et al. (2011). CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature, 475(7355), 222\u2013225.","journal-title":"Nature"},{"issue":"13","key":"10383_CR96","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1158\/1078-0432.CCR-13-0525","volume":"19","author":"DE Sanford","year":"2013","unstructured":"Sanford, D. E., et al. (2013). Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: A role for targeting the CCL2\/CCR2 axis. Clinical Cancer Research, 19(13), 3404\u20133415.","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10383_CR97","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.immuni.2019.01.009","volume":"50","author":"DP Dyer","year":"2019","unstructured":"Dyer, D. P., et al. (2019). Chemokine receptor redundancy and specificity are context dependent. Immunity, 50(2), 378-389.e5.","journal-title":"Immunity"},{"key":"10383_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.993444","volume":"13","author":"GP Takacs","year":"2022","unstructured":"Takacs, G. P., et al. (2022). Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2(+)\/CX3CR1(+) M-MDSCs into the tumor microenvironment in a redundant manner. Frontiers in Immunology, 13, Article 993444.","journal-title":"Frontiers in Immunology"},{"key":"10383_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101089","volume":"59","author":"AG Liner","year":"2025","unstructured":"Liner, A. G., et al. (2025). Non-redundant roles of the CCR1 and CCR2 chemokine axes in monocyte recruitment during lung metastasis. Neoplasia (New York, N.Y.), 59, Article 101089.","journal-title":"Neoplasia (New York, N.Y.)"},{"issue":"1","key":"10383_CR100","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ccr.2008.11.012","volume":"15","author":"JT Erler","year":"2009","unstructured":"Erler, J. T., et al. (2009). Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell, 15(1), 35\u201344.","journal-title":"Cancer Cell"},{"issue":"19","key":"10383_CR101","doi-asserted-by":"publisher","first-page":"7529","DOI":"10.1158\/0008-5472.CAN-08-4382","volume":"69","author":"Y Huang","year":"2009","unstructured":"Huang, Y., et al. (2009). Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Research, 69(19), 7529\u20137537.","journal-title":"Cancer Research"},{"issue":"6","key":"10383_CR102","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1158\/0008-5472.CAN-15-0204","volume":"76","author":"AJ Giles","year":"2016","unstructured":"Giles, A. J., et al. (2016). Activation of hematopoietic stem\/progenitor cells promotes immunosuppression within the pre-metastatic niche. Cancer Research, 76(6), 1335\u20131347.","journal-title":"Cancer Research"},{"issue":"8","key":"10383_CR103","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nri1669","volume":"5","author":"RE Mebius","year":"2005","unstructured":"Mebius, R. E., & Kraal, G. (2005). Structure and function of the spleen. Nature Reviews Immunology, 5(8), 606\u2013616.","journal-title":"Nature Reviews Immunology"},{"issue":"7","key":"10383_CR104","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1073\/pnas.1113744109","volume":"109","author":"V Cortez-Retamozo","year":"2012","unstructured":"Cortez-Retamozo, V., et al. (2012). Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci U S A, 109(7), 2491\u20132496.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10383_CR105","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1172\/JCI97973","volume":"128","author":"C Wu","year":"2018","unstructured":"Wu, C., et al. (2018). Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis. Journal of Clinical Investigation, 128(8), 3425\u20133438.","journal-title":"Journal of Clinical Investigation"},{"issue":"3","key":"10383_CR106","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.celrep.2012.08.006","volume":"2","author":"S Ugel","year":"2012","unstructured":"Ugel, S., et al. (2012). Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Reports, 2(3), 628\u2013639.","journal-title":"Cell Reports"},{"issue":"3","key":"10383_CR107","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.cell.2020.09.058","volume":"183","author":"L Kalafati","year":"2020","unstructured":"Kalafati, L., et al. (2020). Innate immune training of granulopoiesis promotes anti-tumor activity. Cell, 183(3), 771-785.e12.","journal-title":"Cell"},{"issue":"3","key":"10383_CR108","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.cell.2020.09.059","volume":"183","author":"B Priem","year":"2020","unstructured":"Priem, B., et al. (2020). Trained immunity-promoting nanobiologic therapy suppresses tumor growth and potentiates checkpoint inhibition. Cell, 183(3), 786-801.e19.","journal-title":"Cell"},{"issue":"8","key":"10383_CR109","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.ccell.2025.05.002","volume":"43","author":"AW Daman","year":"2025","unstructured":"Daman, A. W., et al. (2025). Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven anti-tumor immunity. Cancer Cell, 43(8), 1442-1459.e10.","journal-title":"Cancer Cell"},{"issue":"8","key":"10383_CR110","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.immuni.2025.05.026","volume":"58","author":"LF Jurado","year":"2025","unstructured":"Jurado, L. F., et al. (2025). A fungal-derived adjuvant amplifies the antitumoral potency of Bacillus Calmette-Gu\u00e9rin via reprogramming granulopoiesis. Immunity, 58(8), 1984-2001.e6.","journal-title":"Immunity"},{"issue":"5","key":"10383_CR111","doi-asserted-by":"publisher","first-page":"440","DOI":"10.2174\/156652410791608243","volume":"10","author":"KR Georgiou","year":"2010","unstructured":"Georgiou, K. R., Foster, B. K., & Xian, C. J. (2010). Damage and recovery of the bone marrow microenvironment induced by cancer chemotherapy - Potential regulatory role of chemokine CXCL12\/receptor CXCR4 signalling. Current Molecular Medicine, 10(5), 440\u201353.","journal-title":"Current Molecular Medicine"},{"issue":"3","key":"10383_CR112","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.stem.2009.01.006","volume":"4","author":"AT Hooper","year":"2009","unstructured":"Hooper, A. T., et al. (2009). Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell, 4(3), 263\u2013274.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10383_CR113","doi-asserted-by":"publisher","first-page":"2230669","DOI":"10.1080\/2162402X.2023.2230669","volume":"12","author":"P Krone","year":"2023","unstructured":"Krone, P., et al. (2023). Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors. Oncoimmunology, 12(1), 2230669.","journal-title":"Oncoimmunology"},{"issue":"1","key":"10383_CR114","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13014-020-01606-3","volume":"15","author":"J Huang","year":"2020","unstructured":"Huang, J., et al. (2020). Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: A single-center prospective randomized controlled trial. Radiation Oncology, 15(1), 180.","journal-title":"Radiation Oncology"},{"issue":"10","key":"10383_CR115","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1136\/gutjnl-2021-326259","volume":"71","author":"J Leslie","year":"2022","unstructured":"Leslie, J., et al. (2022). CXCR2 inhibition enables NASH-HCC immunotherapy. Gut, 71(10), 2093\u20132106.","journal-title":"Gut"},{"issue":"7989","key":"10383_CR116","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/s41586-023-06696-z","volume":"623","author":"C Guo","year":"2023","unstructured":"Guo, C., et al. (2023). Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. Nature, 623(7989), 1053\u20131061.","journal-title":"Nature"},{"issue":"2","key":"10383_CR117","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s13238-015-0237-2","volume":"7","author":"W Li","year":"2016","unstructured":"Li, W., et al. (2016). G-CSF is a key modulator of MDSC and could be a potential therapeutic target in colitis-associated colorectal cancers. Protein & Cell, 7(2), 130\u2013140.","journal-title":"Protein & Cell"},{"issue":"2","key":"10383_CR118","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1073\/pnas.1910856117","volume":"117","author":"JA Flores-Toro","year":"2020","unstructured":"Flores-Toro, J. A., et al. (2020). CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Proceedings of the National Academy of Sciences of the United States of America, 117(2), 1129\u20131138.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10383_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-020-01441-y","volume":"3","author":"MM Tu","year":"2020","unstructured":"Tu, M. M., et al. (2020). Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy. Communications Biology, 3(1), Article 720.","journal-title":"Communications Biology"},{"issue":"3","key":"10383_CR120","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1007\/s10637-012-9869-8","volume":"31","author":"KJ Pienta","year":"2013","unstructured":"Pienta, K. J., et al. (2013). Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Investigational New Drugs, 31(3), 760\u2013768.","journal-title":"Investigational New Drugs"},{"issue":"3","key":"10383_CR121","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10549-024-07555-9","volume":"209","author":"HS Rugo","year":"2025","unstructured":"Rugo, H. S., et al. (2025). Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. Breast Cancer Research and Treatment, 209(3), 487\u2013492.","journal-title":"Breast Cancer Research and Treatment"},{"issue":"1","key":"10383_CR122","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2543614","volume":"14","author":"KM Bever","year":"2025","unstructured":"Bever, K. M., et al. (2025). A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages. OncoImmunology, 14(1), Article 2543614.","journal-title":"OncoImmunology"},{"issue":"8","key":"10383_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2025.100859","volume":"6","author":"JM Lee","year":"2025","unstructured":"Lee, J. M., et al. (2025). CANOPY-N: A phase 2 study of canakinumab or pembrolizumab, alone or in combination, as neoadjuvant therapy in patients with resectable, stage IB-IIIA NSCLC. JTO Clinical Research Reports, 6(8), Article 100859.","journal-title":"JTO Clinical Research Reports"},{"issue":"2","key":"10383_CR124","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1200\/JCO.23.00980","volume":"42","author":"DSW Tan","year":"2024","unstructured":"Tan, D. S. W., et al. (2024). Canakinumab versus placebo in combination with first-line pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer: Results from the CANOPY-1 trial. Journal of Clinical Oncology, 42(2), 192\u2013204.","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10383_CR125","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10637-023-01410-2","volume":"42","author":"AJ Armstrong","year":"2024","unstructured":"Armstrong, A. J., et al. (2024). CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: A phase 2 randomized trial. Investigational New Drugs, 42(1), 145\u2013159.","journal-title":"Investigational New Drugs"},{"issue":"17","key":"10383_CR126","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1158\/1078-0432.CCR-24-1821","volume":"31","author":"PM Grierson","year":"2025","unstructured":"Grierson, P. M., et al. (2025). Neoadjuvant BMS-813160, nivolumab, gemcitabine, and nab-paclitaxel for patients with pancreatic cancer. Clinical Cancer Research, 31(17), 3644\u20133651.","journal-title":"Clinical Cancer Research"},{"key":"10383_CR127","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011284","author":"DT Le","year":"2026","unstructured":"Le, D. T., et al. (2026). Phase 1b\/2 study of BMS-813160, a CCR2\/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer. Journal for Immunotherapy of Cancer. https:\/\/doi.org\/10.1136\/jitc-2024-011284","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"5","key":"10383_CR128","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","volume":"17","author":"TM Nywening","year":"2016","unstructured":"Nywening, T. M., et al. (2016). Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: A single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncology, 17(5), 651\u2013662.","journal-title":"Lancet Oncology"},{"issue":"3","key":"10383_CR129","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s10637-019-00830-3","volume":"38","author":"M Noel","year":"2020","unstructured":"Noel, M., et al. (2020). Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel\/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. Investigational New Drugs, 38(3), 800\u2013811.","journal-title":"Investigational New Drugs"},{"issue":"1","key":"10383_CR130","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11523-014-0320-2","volume":"10","author":"I Brana","year":"2015","unstructured":"Brana, I., et al. (2015). Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: An open-label, multicenter phase 1b study. Targeted Oncology, 10(1), 111\u2013123.","journal-title":"Targeted Oncology"},{"issue":"4","key":"10383_CR131","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00280-013-2099-8","volume":"71","author":"SK Sandhu","year":"2013","unstructured":"Sandhu, S. K., et al. (2013). A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 71(4), 1041\u20131050.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"3","key":"10383_CR132","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.clcc.2024.05.003","volume":"23","author":"A Bessudo","year":"2024","unstructured":"Bessudo, A., et al. (2024). Safety and efficacy of vicriviroc (MK-7690) in combination with pembrolizumab in patients with advanced or metastatic microsatellite stable colorectal cancer. Clinical Colorectal Cancer, 23(3), 285\u2013294.","journal-title":"Clinical Colorectal Cancer"},{"key":"10383_CR133","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejca.2022.03.017","volume":"167","author":"GM Haag","year":"2022","unstructured":"Haag, G. M., et al. (2022). Pembrolizumab and maraviroc in refractory mismatch repair proficient\/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial. European Journal of Cancer, 167, 112\u2013122.","journal-title":"European Journal of Cancer"},{"key":"10383_CR134","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919854238","volume":"11","author":"R Wesolowski","year":"2019","unstructured":"Wesolowski, R., et al. (2019). Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. Therapeutic Advances in Medical Oncology, 11, Article 1758835919854238.","journal-title":"Therapeutic Advances in Medical Oncology"},{"issue":"2","key":"10383_CR135","doi-asserted-by":"publisher","first-page":"73","DOI":"10.36401\/JIPO-23-16","volume":"7","author":"J Ahmed","year":"2024","unstructured":"Ahmed, J., et al. (2024). Phase Ib\/II study of lacnotuzumab in combination with spartalizumab in patients with advanced malignancies. Journal of Immunotherapy of Precision Oncology, 7(2), 73\u201381.","journal-title":"Journal of Immunotherapy of Precision Oncology"},{"issue":"18","key":"10383_CR136","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1158\/1078-0432.CCR-21-0929","volume":"27","author":"B Bockorny","year":"2021","unstructured":"Bockorny, B., et al. (2021). Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT\/KEYNOTE-202 trial. Clinical Cancer Research, 27(18), 5020\u20135027.","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10383_CR137","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/bjc.1995.212","volume":"71","author":"H Yanagawa","year":"1995","unstructured":"Yanagawa, H., et al. (1995). Serum levels of interleukin 6 in patients with lung cancer. British Journal of Cancer, 71(5), 1095\u20131098.","journal-title":"British Journal of Cancer"},{"issue":"12","key":"10383_CR138","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/sj.bjc.6600655","volume":"87","author":"R Salgado","year":"2002","unstructured":"Salgado, R., et al. (2002). Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. British Journal of Cancer, 87(12), 1437\u20131444.","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10383_CR139","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12916-022-02356-7","volume":"20","author":"C Liu","year":"2022","unstructured":"Liu, C., et al. (2022). Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. BMC Medicine, 20(1), 187.","journal-title":"BMC Medicine"},{"issue":"22","key":"10383_CR140","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/1078-0432.CCR-13-3203","volume":"20","author":"MF Sanmamed","year":"2014","unstructured":"Sanmamed, M. F., et al. (2014). Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clinical Cancer Research, 20(22), 5697\u20135707.","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10383_CR141","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1038\/s41467-025-58186-7","volume":"16","author":"K Tanaka","year":"2025","unstructured":"Tanaka, K., et al. (2025). Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC. Nature Communications, 16(1), 2825.","journal-title":"Nature Communications"},{"issue":"19","key":"10383_CR142","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1158\/1078-0432.CCR-24-0902","volume":"31","author":"L Carril-Ajuria","year":"2025","unstructured":"Carril-Ajuria, L., et al. (2025). High circulating IL-6\/IL-8 is associated with intratumoral myeloid contexture and poor outcomes in patients with advanced renal cell carcinoma treated with PD-1 blockade. Clinical Cancer Research, 31(19), 4150\u20134158.","journal-title":"Clinical Cancer Research"},{"issue":"8","key":"10383_CR143","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/j.rmed.2007.02.021","volume":"101","author":"D Miotto","year":"2007","unstructured":"Miotto, D., et al. (2007). CC ligand 2 levels are increased in LPS-stimulated peripheral monocytes of patients with non-small cell lung cancer. Respiratory Medicine, 101(8), 1738\u20131743.","journal-title":"Respiratory Medicine"},{"issue":"3","key":"10383_CR144","first-page":"167","volume":"123","author":"V Chopra","year":"1997","unstructured":"Chopra, V., Dinh, T. V., & Hannigan, E. V. (1997). Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer. Journal of Cancer Research and Clinical Oncology, 123(3), 167\u2013172.","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"13","key":"10383_CR145","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1016\/j.cell.2026.05.005","volume":"189","author":"T Pandya","year":"2026","unstructured":"Pandya, T., et al. (2026). Plasma signals of lung tumor promotion for molecular cancer prevention. Cell, 189(13), 3903-3921.e26.","journal-title":"Cell"},{"issue":"11","key":"10383_CR146","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/s41419-024-07191-7","volume":"15","author":"T Liu","year":"2024","unstructured":"Liu, T., et al. (2024). PD-L2 of tumor-derived exosomes mediates the immune escape of cancer cells via the impaired T cell function. Cell Death & Disease, 15(11), 800.","journal-title":"Cell Death & Disease"},{"issue":"15","key":"10383_CR147","doi-asserted-by":"publisher","first-page":"16405","DOI":"10.1002\/cam4.6275","volume":"12","author":"D Li","year":"2023","unstructured":"Li, D., et al. (2023). Prostate cancer cells synergistically defend against CD8(+) T cells by secreting exosomal PD-L1. Cancer Medicine, 12(15), 16405\u201316415.","journal-title":"Cancer Medicine"},{"issue":"1","key":"10383_CR148","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1186\/s12967-024-05611-y","volume":"22","author":"H Li","year":"2024","unstructured":"Li, H., et al. (2024). The expansion of MDSCs induced by exosomal PD-L1 promotes the progression of gastric cancer. Journal of Translational Medicine, 22(1), 821.","journal-title":"Journal of Translational Medicine"},{"issue":"1","key":"10383_CR149","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13046-024-02991-3","volume":"43","author":"K Li","year":"2024","unstructured":"Li, K., et al. (2024). Tumor-derived exosomal ADAM17 promotes pre-metastatic niche formation by enhancing vascular permeability in colorectal cancer. Journal of Experimental & Clinical Cancer Research, 43(1), 59.","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"1","key":"10383_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54706-z","volume":"15","author":"MX Li","year":"2024","unstructured":"Li, M. X., et al. (2024). Tumor-derived miR-9-5p-loaded EVs regulate cholesterol homeostasis to promote breast cancer liver metastasis in mice. Nature Communications, 15(1), Article 10539.","journal-title":"Nature Communications"},{"issue":"1","key":"10383_CR151","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12967-025-06334-4","volume":"23","author":"T Li","year":"2025","unstructured":"Li, T., et al. (2025). Colorectal cancer cells-derived exosomal miR-188-3p promotes liver metastasis by creating a pre-metastatic niche via activation of hepatic stellate cells. Journal of Translational Medicine, 23(1), 369.","journal-title":"Journal of Translational Medicine"},{"issue":"7578","key":"10383_CR152","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nature15756","volume":"527","author":"A Hoshino","year":"2015","unstructured":"Hoshino, A., et al. (2015). Tumour exosome integrins determine organotropic metastasis. Nature, 527(7578), 329\u2013335.","journal-title":"Nature"},{"issue":"1","key":"10383_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25917-5","volume":"12","author":"B Hamza","year":"2021","unstructured":"Hamza, B., et al. (2021). Measuring kinetics and metastatic propensity of CTCs by blood exchange between mice. Nature Communications, 12(1), Article 5680.","journal-title":"Nature Communications"},{"issue":"16","key":"10383_CR154","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1158\/0008-5472.CAN-11-2393","volume":"72","author":"JD Spicer","year":"2012","unstructured":"Spicer, J. D., et al. (2012). Neutrophils promote liver metastasis via Mac-1-mediated interactions with circulating tumor cells. Cancer Research, 72(16), 3919\u20133927.","journal-title":"Cancer Research"},{"issue":"3","key":"10383_CR155","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrclinonc.2016.144","volume":"14","author":"M Mohme","year":"2017","unstructured":"Mohme, M., Riethdorf, S., & Pantel, K. (2017). Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. Nature Reviews Clinical Oncology, 14(3), 155\u2013167.","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"9","key":"10383_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111298","volume":"40","author":"T Pereira-Veiga","year":"2022","unstructured":"Pereira-Veiga, T., et al. (2022). Circulating tumor cell-blood cell crosstalk: Biology and clinical relevance. Cell Reports, 40(9), Article 111298.","journal-title":"Cell Reports"},{"issue":"1","key":"10383_CR157","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12943-019-0976-4","volume":"18","author":"C Wei","year":"2019","unstructured":"Wei, C., et al. (2019). Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Molecular Cancer, 18(1), 64.","journal-title":"Molecular Cancer"},{"issue":"7","key":"10383_CR158","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1002\/cncr.22543","volume":"109","author":"M Naoe","year":"2007","unstructured":"Naoe, M., et al. (2007). Detection of circulating urothelial cancer cells in the blood using the Cell Search System. Cancer, 109(7), 1439\u20131445.","journal-title":"Cancer"},{"key":"10383_CR159","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.addr.2018.01.011","volume":"125","author":"S Riethdorf","year":"2018","unstructured":"Riethdorf, S., et al. (2018). Clinical applications of the Cell Search platform in cancer patients. Advanced Drug Delivery Reviews, 125, 102\u2013121.","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"1","key":"10383_CR160","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1186\/s12885-020-07059-x","volume":"20","author":"Y Li","year":"2020","unstructured":"Li, Y., et al. (2020). Prognostic value of circulating tumor cells detected with the Cell Search system in esophageal cancer patients: A systematic review and meta-analysis. BMC Cancer, 20(1), 581.","journal-title":"BMC Cancer"},{"key":"10383_CR161","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.963091","volume":"12","author":"Z Li","year":"2022","unstructured":"Li, Z., et al. (2022). The prognostic role of circulating tumor cells in gastric cancer: A meta-analysis. Frontiers in Oncology, 12, Article 963091.","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"10383_CR162","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41523-024-00706-7","volume":"10","author":"T Thomas-Bonafos","year":"2024","unstructured":"Thomas-Bonafos, T., et al. (2024). Circulating tumor cells in breast cancer: Clinical validity and utility. NPJ Breast Cancer, 10(1), 103.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10383_CR163","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2233403","volume":"12","author":"T van den Ende","year":"2023","unstructured":"van den Ende, T., et al. (2023). Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with neoadjuvant PD-L1 checkpoint inhibition. OncoImmunology, 12(1), Article 2233403.","journal-title":"OncoImmunology"},{"key":"10383_CR164","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40425-014-0031-3","volume":"2","author":"SJ Santegoets","year":"2014","unstructured":"Santegoets, S. J., et al. (2014). Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. Journal for Immunotherapy of Cancer, 2, 31.","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"5","key":"10383_CR165","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.ccell.2024.04.008","volume":"42","author":"D Dyikanov","year":"2024","unstructured":"Dyikanov, D., et al. (2024). Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer. Cancer Cell, 42(5), 759-779.e12.","journal-title":"Cancer Cell"},{"issue":"1","key":"10383_CR166","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s44276-024-00058-6","volume":"2","author":"MR Conroy","year":"2024","unstructured":"Conroy, M. R., et al. (2024). Exploring the prognostic impact of absolute lymphocyte count in patients treated with immune-checkpoint inhibitors. BJC Rep, 2(1), 31.","journal-title":"BJC Rep"},{"key":"10383_CR167","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1403771","volume":"15","author":"M M\u00f6ller","year":"2024","unstructured":"M\u00f6ller, M., et al. (2024). Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy: Systematic review and meta-analysis. Frontiers in Immunology, 15, Article 1403771.","journal-title":"Frontiers in Immunology"},{"issue":"s1","key":"10383_CR168","doi-asserted-by":"publisher","first-page":"S283","DOI":"10.3233\/TUB-220044","volume":"46","author":"MJ Duffy","year":"2024","unstructured":"Duffy, M. J. (2024). Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction. Tumour Biology, 46(s1), S283-s295.","journal-title":"Tumour Biology"},{"issue":"3","key":"10383_CR169","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1158\/0008-5472.CAN-21-1718","volume":"82","author":"JC Stadler","year":"2022","unstructured":"Stadler, J. C., et al. (2022). Current and future clinical applications of ctDNA in immuno-oncology. Cancer Research, 82(3), 349\u2013358.","journal-title":"Cancer Research"},{"key":"10383_CR170","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713219","author":"J Dao","year":"2023","unstructured":"Dao, J., et al. (2023). Using cfDNA and ctDNA as oncologic markers: A path to clinical validation. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms241713219","journal-title":"International Journal of Molecular Sciences"},{"key":"10383_CR171","unstructured":"Tie, J., et al., Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2\/3 DYNAMIC-III trial. Nat Med, 2025."},{"issue":"1","key":"10383_CR172","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani, D., et al. (2023). Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nature Medicine, 29(1), 127\u2013134.","journal-title":"Nature Medicine"},{"issue":"2","key":"10383_CR173","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jncc.2024.05.007","volume":"5","author":"Q Zhou","year":"2025","unstructured":"Zhou, Q., et al. (2025). Circulating tumor DNA as a biomarker of prognosis prediction in colorectal cancer: A systematic review and meta-analysis. Journal of the National Cancer Center, 5(2), 167\u2013178.","journal-title":"Journal of the National Cancer Center"},{"issue":"10","key":"10383_CR174","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","volume":"29","author":"V Anagnostou","year":"2023","unstructured":"Anagnostou, V., et al. (2023). CtDNA response after pembrolizumab in non-small cell lung cancer: Phase 2 adaptive trial results. Nature Medicine, 29(10), 2559\u20132569.","journal-title":"Nature Medicine"},{"issue":"7957","key":"10383_CR175","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","volume":"616","author":"C Abbosh","year":"2023","unstructured":"Abbosh, C., et al. (2023). Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature, 616(7957), 553\u2013562.","journal-title":"Nature"},{"issue":"2","key":"10383_CR176","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jmoldx.2024.11.006","volume":"27","author":"Z Qi","year":"2025","unstructured":"Qi, Z., et al. (2025). Analytical and clinical validation of the plasma-based Guardant360 CDx test for assessing HER2 (ERBB2) mutation status in patients with non-small-cell lung cancer for treatment with Trastuzumab Deruxtecan in DESTINY-Lung01\/02. The Journal of Molecular Diagnostics, 27(2), 119\u2013129.","journal-title":"The Journal of Molecular Diagnostics"},{"issue":"6","key":"10383_CR177","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/14737159.2020.1724094","volume":"20","author":"S Torres","year":"2020","unstructured":"Torres, S., et al. (2020). A profile on cobas\u00ae EGFR mutation test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer. Expert Review of Molecular Diagnostics, 20(6), 575\u2013582.","journal-title":"Expert Review of Molecular Diagnostics"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10383-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10383-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10383-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:03:36Z","timestamp":1790841816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-026-10383-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":177,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10383"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10383-6","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"30 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"74"}}